Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Has Average Price Target of $43.46 According to Analysts

Posted by Geri Gentry on Oct 17th, 2026

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $43.46.

A number of brokerages have recently commented on TNGX. William Blair assumed coverage on Tango Therapeutics in a research report on Friday. They issued an “outperform” rating on the stock. Jefferies Financial Group upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the company from $27.00 to $60.00 in a research report on Thursday, June 25th. Wall Street Zen downgraded Tango Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Guggenheim lifted their price target on shares of Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Raymond James Financial downgraded Tango Therapeutics to a “hold” rating in a research note on Thursday, June 25th.

Get Our Latest Analysis on TNGX

Insiders Place Their Bets

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the sale, the insider owned 115,743 shares in the company, valued at approximately $2,832,231.21. This represents a 18.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total value of $198,604.00. Following the completion of the transaction, the insider directly owned 59,121 shares of the company’s stock, valued at approximately $1,431,910.62. This trade represents a 12.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

Several institutional investors have recently bought and sold shares of TNGX. BlackRock Inc. bought a new stake in Tango Therapeutics in the 2nd quarter valued at $388,826,000. TRV GP IV LLC purchased a new stake in Tango Therapeutics in the 2nd quarter worth $120,181,383,000. Jupiter Topco LLC purchased a new stake in Tango Therapeutics in the 2nd quarter worth $157,989,000. Seven Fleet Capital Management LP boosted its holdings in shares of Tango Therapeutics by 302.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company’s stock valued at $95,661,000 after purchasing an additional 2,425,484 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Tango Therapeutics during the 2nd quarter valued at about $62,849,000. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Stock Down 2.9%

Shares of NASDAQ TNGX opened at $22.04 on Friday. The company has a market cap of $3.72 billion, a price-to-earnings ratio of -25.93 and a beta of 1.17. The firm’s fifty day moving average is $23.87 and its 200 day moving average is $25.11. Tango Therapeutics has a 52 week low of $6.69 and a 52 week high of $34.39.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Equities research analysts anticipate that Tango Therapeutics will post -1.41 earnings per share for the current year.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities and activate the immune system against tumors. The company uses functional genomics, including CRISPR-based screening, to identify genetic dependencies that may be selectively targeted in cancer cells while limiting effects on healthy tissue.

Tango’s research and development programs include small-molecule therapies and immuno-oncology candidates designed to address genetically defined cancers.